Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)Business Wire • 06/09/22
EQUITY ALERT: Rosen Law Firm Encourages Verrica Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – VRCABusiness Wire • 06/08/22
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals, Inc. (VRCA) InvestorsBusiness Wire • 06/08/22
VERRICA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 06/08/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc. (VRCA) InvestorsBusiness Wire • 06/07/22
VRCA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.Business Wire • 06/06/22
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 70.4% in 4 WeeksZacks Investment Research • 06/01/22
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Verrica Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 05/31/22
Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Verrica Pharmaceuticals Inc. (VRCA) InvestorsBusiness Wire • 05/27/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of InvestorsBusiness Wire • 05/26/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of InvestorsBusiness Wire • 05/26/22
The Law Offices of Frank R. Cruz Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of InvestorsBusiness Wire • 05/26/22
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLCGlobeNewsWire • 05/25/22
After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA)Zacks Investment Research • 05/16/22
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 WeeksZacks Investment Research • 05/13/22
Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/22
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell CarcinomaGlobeNewsWire • 04/05/22